|Day Low/High||11.80 / 12.65|
|52 Wk Low/High||11.45 / 46.17|
The timing of Schwartz' exit is noteworthy given Galena's admission on Jan. 9 of a criminal investigation of the company by the federal prosecutors into the marketing of Abstral.
Cannabis stocks are not affected by the volatility in prices during earnings season and instead trade on positive data such as potential FDA approval on their pipeline of drugs.
Investors in Insys Therapeutics Inc saw new options begin trading this week, for the March 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the INSY options chain for the new March 17th contracts and identified one put and one call contract of particular interest.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
There was plenty of shame to spread around, but Theranos CEO Elizabeth Holmes' loathsome mix of arrogance, incompetence and duplicity makes her the Worst CEO of 2016.
On December 8, 2016, six former executives of Insys Therapeutics, Inc.
The Canadian marijuana market is poised for growth as the number of registered patients continues grows and as licensed producers find innovative ways to create value for its shareholders.
GW Pharmaceuticals has developed cannabis-based therapies for treating epilepsy and multiple sclerosis.
Jim Cramer finds reasons to like AEP, AMGN, DOW and HEI.
This rally isn't just about Trump, Cramer says. He thinks investors are cheering the economic outlook.
Investors eyeing a purchase of Insys Therapeutics Inc stock, but tentative about paying the going market price of $12.78/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the May 2017 put at the $9 strike, which has a bid at the time of this writing of 95 cents.
Donald Trump was not the only big winner on Election Day. The cannabis industry got a spark as well.
President-elect Trump's vague healthcare policy has put the $3 trillion industry on edge.
The U.S. president elect has said in the past that he favors the legalization of marijuana, and he is unlikely to change his stance significantly.
Cannabis stocks listed on the Nasdaq continued to rally after voters ended prohibition and approved the recreational use of marijuana in California, Massachusetts, Maine and Nevada.
The volume of cannabis stocks listed on the Nasdaq have spiked ahead of the election as voters decide tomorrow on recreational and medical use of marijuana.
Jim Cramer likes YUM; says STZ is more appetizing than MNST
Index funds are great, Jim Cramer says, but he encourages investors to do some smart stock picking.